This year, the company has announced its plans to release 25 more new therapeutic cure stuff. Some of them will be released, according to the statement, in cooperation with pharmaceutical companies of Europe. This was announced by the head of the Board of Directors of the Darnytsia Group company Dmytro Shymkiv at the Innovation Day conference of the European Business Association.
The Darnytsia pharmaceutical company, in the first 3 months of 2021, sold to the market five medicaments intended for treating cardiological, neurological, gastroenterological, and respiratory diseases. The press service of this company reported this.
Thus, in March, they presented a remedy, named Memtek, capable of treating dementia and produced for the Darnytsia company in the European Union.
It was emphasized that new drugs are being produced in accordance with a shift to electronic pharmaceutical document flow, digitalization of research processes in clinics, and monitoring of its use.
The message contains information that the origin of more than half of the launches is carried out in advance, which is 1-3 months for various products.
Darnytsia was founded in 1930. Since 1998, it has been the leader in Ukraine in terms of the volume of medicaments production in physical terms. In total, during 2015-2019, the company produced more than 50 brands related to the pharmaceutical industry by investing in R&D of approximately 1.1 billion. The aggregate is an impressive sum.
It is worth recalling that as a result of the situation with the coronavirus in the previous year, the company changed its production guidelines in order to provide the population with antiviral and antipyretic drugs.
Namely, they began to produce Immustat additionally and sell a large batch of the well-known medicine Paracetamol.
The general view of the problem. The pharmaceutical industry is one of the most profitable industries in Ukraine. It occupies a considerable place in the national economy. The product demand grows regardless of economic and political factors. That determines the attractiveness of this industry for both domestic producers and foreign companies. In the post-crisis period, the pharmaceutical sector has shown one of the best recovery rates and has already outperformed pre-crisis sales. Despite the positive tendency within the country, there is still a lack of innovations, skilled personnel, and compliance with international standards that require funding. Investing in Ukrainian pharmaceuticals is becoming more appealing for foreign investors. Still, numerous macroeconomic and political factors hinder the development of the industry and its entry into the European market as an exporter.